| RA is a kind of invasive,chronic, progressing autoimmune disease with arthrosynovitis and symmetry, destructive arthropathy as its main character. The arthrosynovitis recurrent and continue attacks can make articular cartilage and substance of bone destoried, which would lead a high rate of mutilation and malformation. Vasculitis can involve many body organs, causing systemic disease. For half a century, people have essayed a lot of hypothesis to explain RA, but the nosogenesis of the occurrence and development of RA is still unclear and in need of further research. Therefore the emergence of a kind of antirheumatic medication with better potency becomes necessary, and the crucial part of developing new effective medication and formulating therapeutic measure lays in the investigation and development of effective and reasonable RA model.Interleukin 1β(IL-1β) is the first cytokine derived from synovial membrane which can promote cartilage degradation in vivo. Although the initiator of RA is difficult to perorate, there has been little disagreement about the fact that cytokine network play an essential role in long-term course of the disease. Now, gene therapy with IL-1βr in RA has been permitted by FDA. Rheumatoid arthritis(RA) is a chronic inflammatory cytokine-mediated disease, characterized by uncontrolled proliferation of synoviocytes, infiltration of abundant inflammatory cells and progressive joint erosion. In the pathogenesis of RA, The cytokine network mainly including IL-1,TNF-αand other cytokines contributes to activation of fibroblast-like synoviocytes and further leads to erosion of cartilage and bone. Participate in the immune regulation in addition to outside, IL-1βhave a role to play in many diseases, especially in rheumatoid arthritis. Moreover, the side effect and poor efficiency of traditional pharmacological therapies in treatment of RA has led to the development of anti-cytokine strategies.For better evaluation of IL-1βantibody pharmacology and pharmacodynamic action, and to further study the biological characteristics of IL-1βin animal experiments, on the basis of successfully and efficiently expression of human IL-1β, this study use RT-PCR technology clone mouse interleukin-1βfrom thymocyte that stimulated by LPS successfully. By SUMO vector reconstruction, we can obtain high expression and bioactive soluble mouse protein, whcih will help us for further research and utilization of interleukin-1β.This study also established chicken type II collagen RA animal model in SD rats successfully Through a series of gropes, on the basis of original model, we combine intraperitoneal injection of mouse IL-1βand immunifaction of Chicken collagen (chicken CII+CFA), establishment a new kind of animal model. The disease course of this model is earlier obviously than that only inject the chicken collagen (chicken CII+CFA) model group, and also the inflammatory reaction is more serious. therefore IL-1βmay apply in establishing the RA model, which provided a new method to study the RA pathogenesis and research and development of medication. This research take the arthritis index and anti-CⅡantibody titer, the cell factor level, the organization pathological change and phantom study change as the evaluating indicator, make a comprehensive synthetic evaluation to arthritis model. We detected IL-1β, IL-17 and TNF-αlevel of animal blood serum by ELISA, finally indicated that in the model animal blood serum the anti-CII, IL-1β, IL-17 and TNF-αthe level has the remarkable enhancement, which has an obvious difference with the control group (*P<0.05). The result indicated that this method has enriched the preparation way of RA animal model enormously.
|
PDF Full Text Request